Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Melphalan Dosing in Autologous Transplant for Multiple Myeloma
NCT03328936Phase 2Withdrawn
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Sep 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in multiple myeloma (MM), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Planned start Sep 2018; status: withdrawn.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03328936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328936.